InflaRx N.V. IFRX 深 滬
已收盤 05-08 16:00:00 美东时间
2.58
-0.070
-2.64%
華盛通- 最 高2.80
- 今 開2.62
- 成交量 748.85万股
- 最 低 2.36
- 昨 收 2.65
- 總市值 1.87亿
- 52周最高 2.9489
- 市盈率 靜 --
- 換手率 10.36%
- 52周最低 0.7113
- 委 比 62.73%
- 總股本 7229.29万
- 歷史最高 53.10
- 量 比 1.21
- 振 幅 16.60%
- 歷史最低 0.7113
- 每 手 1
- 風險率 0.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | 伟创力绩后暴涨近40%！NNE大涨27%，与超微电脑联手探索核能AI数据中心
伟创力绩后暴涨近40%！宣布分拆云计算部门独立上市；NNE大涨27%，与超微电脑联手探索核能AI数据中心>>
05-07 19:09
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers GlucoTrack (NASDAQ:GCTK) stock increased by 39.7% to $1.02 during Wedn...
05-07 01:05
InflaRx Prices Underwritten Offering of 75M Shares At $2.00 Per Share
All ordinary shares in the offering are being sold by the Company. The offering is expected to close on May 7, 2026, subject to the satisfaction of customary closing conditions.The Company intends to use the net proceeds
05-06 20:34
InflaRx regains Nasdaq compliance after shares trade above $1
InflaRx N.V. on Tuesday said it had regained compliance with Nasdaq’s minimum bid price requirement, after its shares closed at or above $1.00 for 10 consecutive business days between April 13 and Apr...
04-28 19:53
InflaRx Regains Nasdaq Compliance
InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company"), today announced that it has received a written notice (the "Notice"),
04-28 19:33
美股大行评级 | 瑞银大幅上调西部数据、希捷科技目标价！汇丰银行上调英特尔评级至"买入"，目标价从50美元升至95美元
今日重点评级关注：HC Wainwright & Co.：维持Century Therapeutics"买入"评级，目标价从2美元升至5美元；Oppenheimer：维持Climb Bio"跑赢大市"评级，目标价从10美元升至18美元
04-22 12:41
Guggenheim Reiterates Buy on InflaRx, Maintains $14 Price Target
Guggenheim analyst Yatin Suneja reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $14 price target.
04-21 21:39
10 Health Care Stocks Moving In Friday's Intraday Session
Gainers Psyence Biomedical (NASDAQ:PBM) shares increased by 40.5% to $8.25 dur...
04-18 01:05
InflaRx Announces New In Vitro Findings Demonstrating That Izicopan Does Not Exhibit Time-Dependent Inhibition Of CYP3A4, Indicator For Risk For Ddis And Liver Toxicity
InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan does not exhibit
04-09 19:34
